Incyte sinks on setback for drugs acquired in $750M buyout

BioPharma Dive November 19, 2024
Ben Fidler

The company paused testing of one candidate acquired in its April deal for Escient Pharmaceuticals and scrapped another, delivering a blow to the company’s diversification plans.

Incyte has run into development hurdles with two drugs it acquired earlier this year, setting back the biotechnology company’s plans to branch out from its top-selling medicine.

Incyte said on Monday it will pause enrollment in a Phase 2 study testing a drug codenamed INCB000262 in a chronic form of hives, or urticaria. Incyte stopped the trial because of new results from a toxicology study in animals. The company didn’t detail those findings, but said it’s shared them with the Food and Drug Administration and will work with the regulator to determine the program’s...

Today's Sponsors

Today's Sponsor